Speaking at the 2017 Biotech Showcase™ in San Francisco, Grünenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time
Home » Partnering & Drug Development » Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 20...
Other content in this Stream
BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline
Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strateg
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice
Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transfor
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment
Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors original
Testimonials highlight opportunities for China cross-border collaboration
ChinaBio® Partnering Forum 2017 meets May 31–June 1 in Zhuhai, China. Don’t miss the abundant opportunities to engage with the global life science community and forge valuable cross-border partnership
Report findings provide insight into technological innovations and trends in drug development
Knect365 Life Sciences has released a report offering unique insights into the awareness, perceptions and implementation of technological innovations in the drug development industry. Based on a...
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations
Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies
Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm
Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III
Li Chen, PhD, co-founded Hua Medicine (Shanghai) six years ago with Ge Li, PhD, founder of WuXi AppTec. The company soon in-licensed global rights to a GKA treatment for type 2 diabetes from...
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clin
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy
As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's t
Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress
An interview with Monica Weldon, President of Bridge the Gap – SYNGAP Education and Research Foundation Houston-based Monica Weldon is a mother, wife, former teacher and a rare disease advocate...
BIO-Europe Spring® 2017: Key considerations in microbiome partnering
The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is
Biotechs successfully navigate alternative paths to financing
Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...
Can pharma afford to cure patients instead of treating them?
Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...
Mounting uncertainty threatens research and innovation in medicines
Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...
POLs: Patient opinion leaders emerge as key to success in orphan drug designation
Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...
Facing increased complexity, oncology trial sites tighten up procedures